Section 54
Chapter 53,973

Investigator experiences with financial conflicts of interest in clinical trials

Rochon, P.A.; Sekeres, M.; Hoey, J.; Lexchin, J.; Ferris, L.E.; Moher, D.; Wu, W.; Kalkar, S.R.; Van Laethem, M.; Gruneir, A.; Gold, J.; Maskalyk, J.; Streiner, D.L.; Taback, N.; Chan, A-Wen.

Trials 12: 9


ISSN/ISBN: 1745-6215
PMID: 21226951
DOI: 10.1186/1745-6215-12-9
Accession: 053972944

Download citation:  

Financial conflicts of interest (fCOI) can introduce actions that bias clinical trial results and reduce their objectivity. We obtained information from investigators about adherence to practices that minimize the introduction of such bias in their clinical trials experience. Email survey of clinical trial investigators from Canadian sites to learn about adherence to practices that help maintain research independence across all stages of trial preparation, conduct, and dissemination. The main outcome was the proportion of investigators that reported full adherence to preferred trial practices for all of their trials conducted from 2001-2006, stratified by funding source. 844 investigators responded (76%) and 732 (66%) provided useful information. Full adherence to preferred clinical trial practices was highest for institutional review of signed contracts and budgets (82% and 75% of investigators respectively). Lower rates of full adherence were reported for the other two practices in the trial preparation stage (avoidance of confidentiality clauses, 12%; trial registration after 2005, 39%). Lower rates of full adherence were reported for 7 practices in the trial conduct (35% to 43%) and dissemination (53% to 64%) stages, particularly in industry funded trials. 269 investigators personally experienced (n = 85) or witnessed (n = 236) a fCOI; over 70% of these situations related to industry trials. Full adherence to practices designed to promote the objectivity of research varied across trial stages and was low overall, particularly for industry funded trials.

PDF emailed within 0-6 h: $19.90